What is the aim of MINDACT?
The aim of MINDACT is to show that the simultaneous use of the genomic signature found by the Netherlands Cancer Institute using 70 genes (called “MammaprintTM”) together with the methods currently used at determining which women need further additional chemotherapy after their breast cancer has been surgically removed, and which women don’t, is better than the use of the current methods alone. If this hypothesis is correct, the overall quality of life for many women with breast cancer will be improved, and the health care costs associated with such cancer treatment can be reduced, as up to 20% fewer women will require chemotherapy after their breast cancer has been removed.
